This partnership will co-develop a "neural chipset"—a group of function specific chips designed to work together in multiple applications—and integrate it into a single device. This will first form the electronics of an implantable medical device for treating mixed urinary incontinence, a severe debilitating condition with no singular treatment option currently. Ultimately, it will enable the creation of new device therapies for other medical conditions that can be addressed through the nervous system. 

Dr. Dorian Haci, CEO of MintNeuro, commented: "We are at the cusp of a new era in medical technology, where the power of modular design can lead to unprecedented advancements in bioelectronic interventions for neurological conditions. Our collaboration is not just about creating a new implantable device. We are pioneering the use of semiconductor technology to build a platform that will pave the way for countless future innovations and therapies. Together with our partners, we are committed to bridging the gap between advanced medical research and real-world applications."

Dr. Sean Doherty, Amber’s Director of R&D, added: "We are thrilled to be partnering with the experts at MintNeuro and Imperial on the GOLD project. Developing novel therapies in the active implantable medical device space requires significant time and investment, often development of custom chipsets is beyond scope for early-stage companies. The development of a modular neural chipset designed to combine high-level performance with miniaturised footprints has the potential to bring huge benefits to innovation in this space."

Prof. Timothy Constandinou, Professor of Bioelectronics at Imperial, said: "The GOLD project is exciting and completes the translational journey. I look forward to working closely with our spinout MintNeuro, and partner Amber to bring our chipset architecture for neural implants to market, and most importantly, to the clinic."